Edward Nash Analyst PerformanceManaging Director at Canaccord Genuity GroupEdward Nash is a stock analyst at Canaccord Genuity Group in the medical sector, covering 26 publicly traded companies. Over the past year, Edward Nash has issued 39 stock ratings, including strong buy, buy, and hold recommendations. While full access to Edward Nash's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Edward Nash's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings70 Last 10 YearsBuy Recommendations85.71% 60 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution70RatingsDistribution of strong buy, buy, hold, and sell ratings by Edward Nash.RatingPercentageCount Strong Buy1.4%1 ratings Buy84.3%59 ratings Hold14.3%10 ratings Sell0.0%0 ratingsOut of 70 total stock ratings issued by Edward Nash at Canaccord Genuity Group, the majority (84.3%) have been Buy recommendations, followed by 14.3% Hold and 1.4% Strong Buy.Best & Worst CallsBest Call0000.0%MDGLMay 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%OBSVApr 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ96.2% of companies on NASDAQ25 companiesTSE3.8% of companies on TSE1 companyEdward Nash, an analyst at Canaccord Genuity Group, currently covers 26 companies listed on NASDAQ and TSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical26 companies100.0%Edward Nash of Canaccord Genuity Group specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE17 companies65.4%MED - DRUGS4 companies15.4%PHARMACEUTICAL PREPARATIONS2 companies7.7%MED PRODUCTS1 company3.8%DRUG MANUFACTURERS - SPECIALTY & GENERIC1 company3.8%BIOTECHNOLOGY1 company3.8% Edward Nash's Ratings History at Canaccord Genuity Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsAPGEApogee Therapeutics6/22/2026Downgrade$132.65$135.11Hold$0.0000.00% ROIVERUVeru6/4/2026Reiterated Rating$5.57$25.00Buy$0.0000.00% ROICORTCorcept Therapeutics5/28/2026Boost Price Target$69.46$135.00Buy$0.0000.00% ROICNTBConnect Biopharma5/26/2026Initiated Coverage$2.35$6.00Buy$0.0000.00% ROICNTBConnect Biopharma5/26/2026Initiated Coverage$2.40$6.00Buy$0.0000.00% ROIRANIRani Therapeutics5/20/2026Reiterated Rating$1.04$5.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals5/7/2026Lower Price Target$539.73$578.00Buy$0.0000.00% ROIKYMRKymera Therapeutics5/6/2026Initiated Coverage$82.71$106.00Buy$0.0000.00% ROISGMTSagimet Biosciences5/4/2026Boost Price Target$7.74$49.00Buy$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/29/2026Boost Price Target$52.54$64.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. GPCRStructure Therapeutics4/27/2026Initiated Coverage$45.49$101.00Buy$0.0000.00% ROIGPCRStructure Therapeutics4/27/2026Upgrade$43.56$101.00Strong-Buy$0.0000.00% ROITVTXTravere Therapeutics4/14/2026Boost Price Target$40.97$56.00Buy$0.0000.00% ROICRDLCardiol Therapeutics4/6/2026Reiterated Rating$1.37$8.00Buy$0.0000.00% ROIRANIRani Therapeutics4/1/2026Lower Price Target$0.81$5.00Buy$0.0000.00% ROICORTCorcept Therapeutics3/26/2026Boost Price Target$38.74$110.00Buy$0.0000.00% ROIAPGEApogee Therapeutics3/24/2026Boost Price Target$73.74$130.00Buy$0.0000.00% ROIPLRXPliant Therapeutics3/13/2026Lower Price Target$1.36$3.00Hold$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International2/19/2026Initiated Coverage$45.39$62.00Buy$0.0000.00% ROICORTCorcept Therapeutics1/23/2026Boost Price Target$41.30$100.00Buy$0.0000.00% ROIVTYXVentyx Biosciences1/8/2026Downgrade$13.73$14.00Hold$0.0000.00% ROICORTCorcept Therapeutics1/2/2026Lower Price Target$34.80$99.00Buy$0.0000.00% ROIVERUVeru12/18/2025Initiated Coverage$2.23$25.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals11/13/2025Boost Price Target$514.84$587.00Buy$0.0000.00% ROIVKTXViking Therapeutics11/12/2025Boost Price Target$40.60$107.00Buy$0.0000.00% ROIVTYXVentyx Biosciences11/7/2025Boost Price Target$8.77$16.00Buy$0.0000.00% ROIVKTXViking Therapeutics10/29/2025Initiated Coverage$34.93$106.00Buy$0.0000.00% ROIAKROAkero Therapeutics10/9/2025Downgrade$54.24$54.00Hold$0.0000.00% ROISGMTSagimet Biosciences10/2/2025Reiterated Rating$6.98$28.00Buy$0.0000.00% ROIIVAInventiva9/30/2025Reiterated Rating$5.71$20.00Buy$0.0000.00% ROICORTCorcept Therapeutics9/25/2025Reiterated Rating$83.84$140.00Buy$0.0000.00% ROICLDXCelldex Therapeutics9/17/2025Reiterated Rating$24.64$62.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals9/12/2025Boost Price Target$439.45$526.00Buy$0.0000.00% ROICORTCorcept Therapeutics9/10/2025Boost Price Target$73.48$140.00Buy$0.0000.00% ROICLDXCelldex Therapeutics8/20/2025Lower Price Target$22.11$62.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals8/6/2025Boost Price Target$335.67$428.00Buy$0.0000.00% ROICORTCorcept Therapeutics8/1/2025Lower Price Target$68.52$137.00Buy$0.0000.00% ROISGMTSagimet Biosciences7/24/2025Initiated Coverage$9.59$28.00Buy$0.0000.00% ROIVRNAVerona Pharma PLC American Depositary Share7/9/2025Downgrade$104.77$107.00Hold$0.0000.00% ROIMDGLMadrigal Pharmaceuticals5/2/2025Boost Price Target$327.81$420.00Buy$000.0000.00% ROIA letter from Shannon Stansberry (Ad)Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.Watch the full story and see the verified track record for yourselfCLDXCelldex Therapeutics4/28/2025Initiated Coverage$19.57$64.00Buy$00.0000.00% ROITVTXTravere Therapeutics4/10/2025Boost Price Target$13.42$47.00Buy$00.0000.00% ROICORTCorcept Therapeutics4/1/2025Boost Price Target$102.62$142.00Buy$00.0000.00% ROIRANIRani Therapeutics2/26/2025Reiterated Rating$1.55$9.00Buy$0.0000.00% ROIVRNAVerona Pharma PLC American Depositary Share2/12/2025Boost Price Target$59.33$72.00Buy$0.0000.00% ROITVTXTravere Therapeutics2/12/2025Boost Price Target$23.75$45.00Buy$00.0000.00% ROIPLRXPliant Therapeutics2/10/2025Reiterated Rating$7.79$4.00Hold$0.0000.00% ROICORTCorcept Therapeutics1/30/2025Boost Price Target$69.89$130.00Buy$00.0000.00% ROIAKROAkero Therapeutics1/28/2025Boost Price Target$51.37$73.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausDeutsche Bank Aktiengesellschaft Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
